Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL) cholesterol levels but is associated with increased blood pressure. In a phase 3 clinical study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib. The studies reported herein sought to evaluate off‐target effects of torcetrapib.

[1]  M. Kamada,et al.  Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits* , 1998, The Journal of Biological Chemistry.

[2]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[3]  G. Assmann,et al.  Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. , 1992, The American journal of cardiology.

[4]  J. Funder,et al.  The Pathophysiology of Aldosterone in the Cardiovascular System , 2002, Annals of the New York Academy of Sciences.

[5]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[6]  E. Schiffrin.  Effects of Aldosterone on the Vasculature , 2006, Hypertension.

[7]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[8]  J. Connell,et al.  The new biology of aldosterone. , 2005, The Journal of endocrinology.

[9]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[10]  R. Coleman,et al.  Effect of Eplerenone, a Selective Aldosterone Blocker, on Blood Pressure, Serum and Macrophage Oxidative Stress, and Atherosclerosis in Apolipoprotein E–Deficient Mice , 2003, Journal of cardiovascular pharmacology.

[11]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[12]  M. Ullian.  The role of corticosteriods in the regulation of vascular tone. , 1999, Cardiovascular research.

[13]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[14]  K. Catt,et al.  Aldosterone production by isolated adrenal glomerulosa cells: stimulation by physiological concentrations of angiotensin II. , 1975, Endocrinology.

[15]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[16]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[17]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[18]  D. Levy,et al.  Serum aldosterone and the incidence of hypertension in nonhypertensive persons. , 2004, The New England journal of medicine.

[19]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[20]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[21]  Gregory T O'Donnell,et al.  A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. , 2007, Analytical biochemistry.

[22]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[23]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. , 2006, Journal of the American College of Cardiology.

[24]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[25]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[26]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[27]  T. Hayama,et al.  Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[29]  D. Stocco,et al.  Regulation of the acute production of steroids in steroidogenic cells. , 1996, Endocrine reviews.

[30]  D. Pollock,et al.  A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat , 1970, British journal of pharmacology.

[31]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[32]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. , 2006, Journal of the American College of Cardiology.